Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A new page revision tag v3.5.4 is added, replacing v3.5.3, indicating an updated version of the study page.
    Difference
    0.1%
    Check dated 2026-05-18T03:53:00.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page’s displayed release/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a site/system update rather than a change to the study record content.
    Difference
    0.1%
    Check dated 2026-04-26T15:19:52.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Revision number updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-19T13:36:41.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Removed Hepatocellular carcinoma from the Conditions list and removed the Genetic and Rare Diseases Information Center resource under Resources.
    Difference
    0.2%
    Check dated 2026-03-28T23:40:08.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Added the MeSH term 'Hepatocellular carcinoma' and a link to the Genetic and Rare Diseases Information Center; updated page revision from v3.4.3 to v3.5.0.
    Difference
    0.2%
    Check dated 2026-03-21T15:41:36.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Updated site revision from v3.4.2 to v3.4.3. No visible changes to the study details page.
    Difference
    0.1%
    Check dated 2026-03-06T21:06:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.